D Campana

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Characterization of CD34+, CD13+, CD33- cells, a rare subset of immature human hematopoietic cells
    Giuseppe Gaipa
    Centro Ricerca M Tettamanti, Clinica Pediatrica, Universita Milano Bicocca, Ospedale San Gerardo, Via Donizetti 106, 20052 Monza MI, Italy
    Haematologica 87:347-56. 2002
  2. doi request reprint Minimal residual disease monitoring in childhood acute lymphoblastic leukemia
    Dario Campana
    Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    Curr Opin Hematol 19:313-8. 2012
  3. pmc Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity
    Caroline J Voskens
    Department of Pathology, University of Maryland School of Medicine, 10 South Pine Street, Baltimore, MD 21201, USA
    J Exp Clin Cancer Res 29:134. 2010
  4. ncbi request reprint Minimal residual disease studies by flow cytometry in acute leukemia
    Dario Campana
    Department of Hematology Oncology, St Jude Children s Research Hospital, University of Tennessee College of Medicine, Memphis, TN 38105, USA
    Acta Haematol 112:8-15. 2004
  5. ncbi request reprint ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells
    Dario Campana
    Hematology Oncology and Pathology, St Jude Children s Research Hospital, University of Tennessee College of Medicine, Lauderdale, Memphis TN 38105, USA
    Haematologica 90:867. 2005
  6. pmc Minimal residual disease in acute lymphoblastic leukemia
    Dario Campana
    Department of Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Semin Hematol 46:100-6. 2009
  7. pmc Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia
    Dario Campana
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Hematol Oncol Clin North Am 23:1083-98, vii. 2009
  8. pmc Status of minimal residual disease testing in childhood haematological malignancies
    Dario Campana
    Department of Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Br J Haematol 143:481-9. 2008
  9. ncbi request reprint Immunophenotyping of leukemia
    D Campana
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, 38105, Memphis, TN, USA
    J Immunol Methods 243:59-75. 2000
  10. ncbi request reprint Detection of minimal residual disease in acute leukemia by flow cytometry
    D Campana
    Department of Hematology Oncology, Medicine, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cytometry 38:139-52. 1999

Research Grants

Detail Information

Publications74

  1. ncbi request reprint Characterization of CD34+, CD13+, CD33- cells, a rare subset of immature human hematopoietic cells
    Giuseppe Gaipa
    Centro Ricerca M Tettamanti, Clinica Pediatrica, Universita Milano Bicocca, Ospedale San Gerardo, Via Donizetti 106, 20052 Monza MI, Italy
    Haematologica 87:347-56. 2002
    ..We noted the presence of CD34+ cells expressing CD13 but lacking CD33, a subset of cells not yet well characterized. In this report we describe the prevalence and the immunophenotype of this cell subset...
  2. doi request reprint Minimal residual disease monitoring in childhood acute lymphoblastic leukemia
    Dario Campana
    Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    Curr Opin Hematol 19:313-8. 2012
    ..This review summarizes recent advances in the application of minimal residual disease (MRD) testing in childhood acute lymphoblastic leukemia (ALL)...
  3. pmc Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity
    Caroline J Voskens
    Department of Pathology, University of Maryland School of Medicine, 10 South Pine Street, Baltimore, MD 21201, USA
    J Exp Clin Cancer Res 29:134. 2010
    ....
  4. ncbi request reprint Minimal residual disease studies by flow cytometry in acute leukemia
    Dario Campana
    Department of Hematology Oncology, St Jude Children s Research Hospital, University of Tennessee College of Medicine, Memphis, TN 38105, USA
    Acta Haematol 112:8-15. 2004
    ..Here we review the relative advantages and disadvantages of flow cytometry for MRD studies, as well as results obtained in correlative studies with treatment outcome...
  5. ncbi request reprint ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells
    Dario Campana
    Hematology Oncology and Pathology, St Jude Children s Research Hospital, University of Tennessee College of Medicine, Lauderdale, Memphis TN 38105, USA
    Haematologica 90:867. 2005
  6. pmc Minimal residual disease in acute lymphoblastic leukemia
    Dario Campana
    Department of Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Semin Hematol 46:100-6. 2009
    ....
  7. pmc Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia
    Dario Campana
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Hematol Oncol Clin North Am 23:1083-98, vii. 2009
    ..This article discusses practical issues related to MRD methodologies and the evidence supporting the use of MRD for risk assignment in clinical trials...
  8. pmc Status of minimal residual disease testing in childhood haematological malignancies
    Dario Campana
    Department of Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Br J Haematol 143:481-9. 2008
    ....
  9. ncbi request reprint Immunophenotyping of leukemia
    D Campana
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, 38105, Memphis, TN, USA
    J Immunol Methods 243:59-75. 2000
    ..The presence of cells expressing these phenotypes in patients who are in clinical remission is associated with an increased risk of relapse...
  10. ncbi request reprint Detection of minimal residual disease in acute leukemia by flow cytometry
    D Campana
    Department of Hematology Oncology, Medicine, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cytometry 38:139-52. 1999
    ..In this review, we discuss methodologic aspects and clinical results of flowcytometric detection of MRD in patients with acute leukemia...
  11. doi request reprint Role of minimal residual disease evaluation in leukemia therapy
    Dario Campana
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Curr Hematol Malig Rep 3:155-60. 2008
    ..This article discusses the methodologies available for productive MRD testing and the clinical significance of the results...
  12. doi request reprint Minimal residual disease in acute lymphoblastic leukemia
    Dario Campana
    Department of Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Hematology Am Soc Hematol Educ Program 2010:7-12. 2010
    ..The time points at which MRD testing is performed and the threshold levels that trigger treatment intensification vary according to the methodology available, the results of preclinical correlative studies, and protocol design...
  13. doi request reprint Progress of minimal residual disease studies in childhood acute leukemia
    Dario Campana
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Curr Hematol Malig Rep 5:169-76. 2010
    ....
  14. pmc Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study
    J T Sandlund
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:1127-30. 2009
    ..The treatment described here produces high cure rates in children with lymphoblastic lymphoma without the use of prophylactic cranial irradiation...
  15. pmc Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia
    C H Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 24:371-82. 2010
    ..The next main challenge is to further increase cure rates while improving quality of life for all patients...
  16. pmc Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial
    J E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 23:1410-6. 2009
    ..For all patients, 5-year event-free survival and overall survival estimates were 44.1+/-5.4 and 50.0+/-5.5%. Our results suggest that cladribine in combination with continuous-infusion cytarabine is effective therapy for childhood AML...
  17. ncbi request reprint Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia
    J S Chen
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 97:2115-20. 2001
    ..These results indicate that studies of gene expression with cDNA arrays can aid the discovery of leukemia markers. (Blood. 2001;97:2115-2120)..
  18. ncbi request reprint Genetic modification of T cells for cancer therapy
    C Imai
    Departments of Hematology Oncology, University of Tennessee College of Medicine, Memphis, TN, USA
    J Biol Regul Homeost Agents 18:62-71. 2004
    ..We here review the principles and methodologies for designing chimeric receptors and delivering them into immune cells, as well as some of the potential complications associated with this form of cell therapy...
  19. ncbi request reprint An essential role for BLNK in human B cell development
    Y Minegishi
    Department of Immunology, Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Science 286:1954-7. 1999
    ..The immune system and overall growth and development were otherwise normal in this patient, suggesting that BLNK function is highly specific...
  20. ncbi request reprint Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells
    A Manabe
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38101
    Blood 83:758-66. 1994
    ..These results establish direct contact with stroma as a survival requirement of normal B lymphoblasts and show marked heterogeneity in stromal dependency among B-lineage leukemic cells...
  21. pmc Mutations in Igalpha (CD79a) result in a complete block in B-cell development
    Y Minegishi
    Departments of Immunology, Hematology Oncology, and Pathology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Clin Invest 104:1115-21. 1999
    ..Furthermore, they suggest that Igalpha does not play a critical role in B-cell development until it is expressed, along with mu heavy chain, as part of the pre-BCR...
  22. ncbi request reprint Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia
    C Imai
    Department of Hematology Oncology, St Jude Children s Research Hospital, North Lauderdale, Memphis, TN 38105 2794, USA
    Leukemia 18:922-5. 2004
    ..These results indicate that BLNK deficiency is a rare occurrence in childhood B-lineage ALL and is unlikely to be a common leukemogenic event as previously proposed...
  23. ncbi request reprint Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
    C Imai
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 18:676-84. 2004
    ..We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19+ B-lymphoid malignancies...
  24. pmc Ligation of CD38 suppresses human B lymphopoiesis
    M Kumagai
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38101
    J Exp Med 181:1101-10. 1995
    ....
  25. pmc ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy
    D Bhojwani
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 26:265-70. 2012
    ....
  26. ncbi request reprint Determination of minimal residual disease in leukaemia patients
    Dario Campana
    Departments of Hematology Oncology and Pathology, St Jude Children s Research Hospital, University of Tennessee College of Medicine, Memphis, TN, USA
    Br J Haematol 121:823-38. 2003
  27. pmc Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia
    Jun J Yang
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    JAMA 301:393-403. 2009
    ..Pediatric acute lymphoblastic leukemia (ALL) is the prototype for a drug-responsive malignancy. Although cure rates exceed 80%, considerable unexplained interindividual variability exists in treatment response...
  28. ncbi request reprint CD38-mediated growth suppression of B-cell progenitors requires activation of phosphatidylinositol 3-kinase and involves its association with the protein product of the c-cbl proto-oncogene
    A Kitanaka
    Department of Hematology Oncology, St Jude Children s Research Hospital Memphis, TN 38105 2794, USA
    Blood 88:590-8. 1996
    ....
  29. ncbi request reprint Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia
    Elaine Coustan-Smith
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Br J Haematol 123:243-52. 2003
    ..022); overt recurrence of AML within the subsequent 6 months was significantly more likely in the former group. The assay described here holds promise for guiding the choice of post-remission treatment options in children with AML...
  30. pmc A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome
    Elaine Coustan-Smith
    Department of Hematology Oncology, and International Outreach Progrm, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 108:97-102. 2006
    ..Thus, this new assay would enable most treatment centers to identify a high proportion of children with ALL who have an excellent early treatment response and a high likelihood of cure...
  31. ncbi request reprint Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells
    T Suzuki
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 16:1276-84. 2002
    ..0% +/- 1.3% (n = 6) in KOPN55bi. CD32 ligation also reduced cell recovery in five of seven CD32(+) primary leukemia samples. Thus, FcgammaRIIA mediates signals that suppress the growth of lymphoid leukemia cells...
  32. pmc Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1
    S Jeha
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:1406-9. 2009
    ..These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse...
  33. ncbi request reprint Expression and activation of the nonreceptor tyrosine kinase Tec in human B cells
    A Kitanaka
    Department of Hematology Oncology, St Jude Children s Research Hospital, Lauderdale, Memphis, TN 38105, USA
    Blood 91:940-8. 1998
    ..We conclude that Tec is expressed and can be stimulated throughout human B-cell differentiation, implying that this tyrosine kinase plays a role in B-cell development and activation...
  34. ncbi request reprint Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia
    C H Pui
    Dept of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Ann Hematol 83:S124-6. 2004
    ....
  35. ncbi request reprint Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia
    G A M Neale
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 18:934-8. 2004
    ..The use of the two methods in tandem ensures MRD monitoring in all patients...
  36. ncbi request reprint Minimal residual disease studies in acute leukemia
    Dario Campana
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Am J Clin Pathol 122:S47-57. 2004
    ..This article discusses the relative merits of the available MRD assays and the significance of MRD in relation to clinical and biologic features of the disease, and treatment outcome...
  37. ncbi request reprint Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia
    Elaine Coustan-Smith
    Department of Hematology Oncology, St Jude Children s Research Hospital and the University of Tennessee, Memphis, TN 38105, USA
    Blood 100:52-8. 2002
    ..Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome...
  38. pmc Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2
    Christian Flotho
    Department of Pathology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Blood 108:1050-7. 2006
    ..Therefore, this gene is a strong candidate for inclusion in gene expression arrays specifically designed for leukemia diagnosis...
  39. ncbi request reprint The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis
    C Ito
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 16:1344-52. 2002
    ..Thus, clotrimazole is cytotoxic to ALL cells at concentrations achievable in vivo...
  40. ncbi request reprint Childhood acute lymphoblastic leukaemia--current status and future perspectives
    C H Pui
    Leukaemia Lymphoma Division, Fahad Nassar Al Rashid Chair of Leukaemia Research at St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 2:597-607. 2001
    ..Ultimately, treatment based on biological features of leukaemic cells, host genetics, and the amount of residual disease should improve cure rates further...
  41. ncbi request reprint Childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA
    Rev Clin Exp Hematol 6:161-80; discussion 200-2. 2002
    ..In the interim, prospective clinical trials have provided valuable clues that are further increasing the cure rate of childhood acute lymphoblastic leukemia...
  42. doi request reprint Primary B cell immunodeficiencies: comparisons and contrasts
    Mary Ellen Conley
    Department of Pediatrics, University of Tennessee College of Medicine, Memphis, Tennessee 38163, USA
    Annu Rev Immunol 27:199-227. 2009
    ..Identifying the genetic and environmental factors that influence the clinical phenotype may enhance patient care and our understanding of normal B cell development...
  43. pmc Treating childhood acute lymphoblastic leukemia without cranial irradiation
    Ching Hon Pui
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 360:2730-41. 2009
    ..Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse...
  44. ncbi request reprint Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 104:2690-6. 2004
    ..01% or more at the end of the 6-week remission induction phase. Our results suggest the efficacy of early intensification of intrathecal chemotherapy and provide the basis for studies omitting cranial irradiation altogether...
  45. pmc Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN 38105 2794, USA
    Lancet Oncol 11:543-52. 2010
    ....
  46. ncbi request reprint Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:7936-41. 2005
    ..Our goal was to use the information to further refine therapy and advance cure rates...
  47. pmc Improved prognosis for older adolescents with acute lymphoblastic leukemia
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:386-91. 2011
    ..We reviewed the outcome of older adolescents (age 15 to 18 years) treated in four consecutive Total Therapy studies to determine if recent improved treatment extended to this high-risk group...
  48. pmc Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing
    Stan Pounds
    Department of Biostatistics, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Int J Data Min Bioinform 5:143-57. 2011
    ..In the analysis of a paediatric leukaemia data set, PROMISE effectively identifies genomic features that exhibit a biologically meaningful pattern of association with multiple endpoint variables...
  49. pmc Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 113:5083-9. 2009
    ..We also suggest that hematopoietic stem cell transplantation is often not required for cure of these patients...
  50. doi request reprint Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Cancer 112:1983-91. 2008
    ..The authors evaluated the response rate, toxicity, and pharmacokinetics of topotecan given before standard induction therapy for childhood acute lymphoblastic leukemia (ALL) in first relapse...
  51. pmc A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia
    Christian Flotho
    Departments of Pathology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 110:1271-7. 2007
    ..Incorporation of the expression levels of these genes into existing strategies of risk classification could improve clinical management...
  52. ncbi request reprint Monitoring minimal residual disease in pediatric hematologic malignancies
    Dario Campana
    St Jude Children s Research Hospital, University of Tennessee, Memphis, TN, USA
    Clin Adv Hematol Oncol 5:876-7, 915. 2007
  53. pmc Minimal residual disease quantitation in acute myeloid leukemia
    David Shook
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Clin Lymphoma Myeloma 9:S281-5. 2009
    ..Other clinically informative uses of MRD testing include the detection of early relapse and the evaluation of the efficacy of new antileukemic agents...
  54. ncbi request reprint Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse
    E Coustan-Smith
    Department of Hematology Oncology, Children s Research Hospital, Memphis, TN, USA
    Leukemia 18:499-504. 2004
    ..We conclude that MRD assays should be used to guide the selection of postremission therapy in patients with ALL in first relapse...
  55. pmc Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia
    Y Minegishi
    Department of Immunology, St Jude Children s Research Hospital, Memphis, Tennesse 38105, USA
    J Exp Med 187:71-7. 1998
    ..1. These findings indicate that expression of the functional lambda5/14.1 is critical for B cell development in the human...
  56. pmc Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase
    Shotaro Iwamoto
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Clin Invest 117:1049-57. 2007
    ..These results provide what we believe to be a new basis for understanding asparaginase resistance in ALL and indicate that MSC niches in the bone marrow can form a safe haven for leukemic cells...
  57. pmc Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
    Patricia Stow
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Blood 115:4657-63. 2010
    ..047). Thus, low levels of MRD (0.001%-< 0.01%) at the end of remission induction therapy have prognostic significance in childhood ALL, suggesting that patients with this finding should be monitored closely for adverse events...
  58. ncbi request reprint Synthetic messenger RNA as a tool for gene therapy
    Peter M Rabinovich
    Department of Genetics, Yale University School of Medicine, New Haven, CT 06520, and Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Hum Gene Ther 17:1027-35. 2006
    ..The transfected mRNA conferred powerful cytotoxicity to T cells against CD19+ targets from the same donor. These results demonstrate that this method can be applied to generate autologous T lymphocytes directed toward malignant cells...
  59. pmc Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia
    Charles G Mullighan
    Department of Pathology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    N Engl J Med 360:470-80. 2009
    ..Recent genomewide analyses have identified a high frequency of DNA copy-number abnormalities in ALL, but the prognostic implications of these abnormalities have not been defined...
  60. pmc Replicative potential of human natural killer cells
    Hiroyuki Fujisaki
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis TN 38105, USA
    Br J Haematol 145:606-13. 2009
    ..We suggest that the methods described here should have many applications in studies of NK cell biology and NK cell-based therapies...
  61. ncbi request reprint Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia
    Dario Campana
    Departments of Hematology Oncology and Pathology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Best Pract Res Clin Haematol 15:1-19. 2002
    ..A strong correlation between flow cytometric measurements of MRD during clinical remission and treatment outcome has been demonstrated, suggesting that these assays should be incorporated into treatment protocols...
  62. ncbi request reprint Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
    Eng Juh Yeoh
    Department of Pathology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer Cell 1:133-43. 2002
    ..Thus, the single platform of expression profiling should enhance the accurate risk stratification of pediatric ALL patients...
  63. pmc Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
    Elaine Coustan-Smith
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 10:147-56. 2009
    ..We studied leukaemic cells, collected at diagnosis, to identify cases with ETP features and determine their clinical outcome...
  64. pmc Natural killer cell engineering for cellular therapy of cancer
    D R Shook
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Tissue Antigens 78:409-15. 2011
    ..Summarized are current efforts for NK cell immunotherapy for cancer and future perspectives...
  65. pmc Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
    Chihaya Imai
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Blood 106:376-83. 2005
    ..Our findings indicate that enforced expression of signaling receptors by NK cells might circumvent inhibitory signals, providing a novel means to enhance the effectiveness of allogeneic stem cell transplantation...
  66. pmc Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group
    Elaine Coustan-Smith
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis TN 38105, USA
    J Clin Oncol 27:3533-9. 2009
    ..Measurements of disease dissemination at diagnosis might provide useful prognostic information, which can be further refined by monitoring response to therapy through blood testing...
  67. pmc Cytotoxicity of activated natural killer cells against pediatric solid tumors
    Duck Cho
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Clin Cancer Res 16:3901-9. 2010
    ..We sought to identify the most sensitive tumor subtypes, clarify the molecular interactions regulating cytotoxicity, and determine NK antitumor potential in vivo...
  68. ncbi request reprint Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia
    Elaine Coustan-Smith
    Departments of Hematology Oncology, Biostatistics, and Pathology, St Jude Children s Research Hospital, and the University of Tennessee, Memphis TN 38105 2794, USA
    Blood 100:2399-402. 2002
    ..007). These results indicate that peripheral blood may be used to monitor MRD in patients with T-lineage ALL and that peripheral blood MRD may provide strong prognostic information in patients with B-lineage ALL...
  69. ncbi request reprint Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia
    Mauro Krampera
    Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Universita di Verona
    Haematologica 91:1109-12. 2006
    ..2%). Blast phenotypes were stable in culture and at relapse, and were useful for MRD monitoring in patients. Marker combinations for childhood ALL are also applicable to adult cases...
  70. ncbi request reprint Minimal residual disease monitoring by flow cytometry
    María B Vidriales
    Department of Haematology, University Hospital, Paseo de San Vicente 58 182, 37007, Salamanca, Spain
    Best Pract Res Clin Haematol 16:599-612. 2003
    ..Current knowledge indicates that MRD studies using well-tested methodologies are clinically useful and should be incorporated into the clinical management of patients with acute leukaemia...
  71. pmc Pharmacogenetics of outcome in children with acute lymphoblastic leukemia
    Jose Claudio C Rocha
    Department of Pharmaceutical Sciences, Saint Jude Children s Research Hospital of the University of Tennessee, Memphis 38105 2794, USA
    Blood 105:4752-8. 2005
    ..04). The GSTM1 non-null and TYMS 3/3 genotypes are plausibly linked to drug resistance. Polymorphisms interact to influence antileukemic outcome and represent determinants of response that can be used to optimize therapy...
  72. ncbi request reprint Minimal residual disease detection in acute lymphoblastic leukemia: real improvement with the real-time quantitative PCR method?
    Geoffrey A M Neale
    J Pediatr Hematol Oncol 25:100-2. 2003
  73. ncbi request reprint Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR
    Gunter Kerst
    Department of Pediatric Haematology and Oncology, University Children s Hospital, D 72076 Tubingen, Germany
    Br J Haematol 128:774-82. 2005
    ..We conclude that both MRD assays yield generally concordant results. Their combined use should enable MRD monitoring in virtually all patients and prevent false-negative results due to clonal evolution or phenotypic shifts...
  74. ncbi request reprint Growth requirements and immunophenotype of acute lymphoblastic leukemia progenitors
    Dario Campana
    Blood 105:4150. 2005

Research Grants34

  1. Beta CELL PROGENITORS AND BONE MARROW MICROENVIRONMENT
    Dario Campana; Fiscal Year: 2004
    ..The proposed studies will further characterize the antileukemic activity of BAY 36-1677 and identify synergistically interacting compounds. ..
  2. IMMUNOGLOBULIN GENE ARRANGEMENT/EXPRESSION IN LEUKEMIA
    Dario Campana; Fiscal Year: 2005
    ..The development of new automated MRD assays and the identification of new markers of leukemia should improve residual disease evaluation and thereby improve risk-directed therapy selection for every child with ALL. ..
  3. DETECTION AND THERAPY OF RESIDUAL LEUKEMIA IN CHILDREN
    Dario Campana; Fiscal Year: 2006
    ..Success in this endeavor could radically improve remission studies in these patients by overcoming the practical and ethical constraints posed by sequential bone marrow aspirations ..
  4. Cell Therapy of Refractory Leukemia
    Dario Campana; Fiscal Year: 2007
    ..The research proposed should not only spur clinical studies of immune cells in patients with refractory ALL but also facilitate the development of effective cell therapies for other neoplasms. ..
  5. Clinical Significance of Residual Myeloid Leukemia
    Dario Campana; Fiscal Year: 2007
    ..Studies in this aim will determine whether higher levels of blood MRD and of circulating leukemic stem cells correlate with a higher risk of relapse. ..
  6. Cell Therapy of Refractory Leukemia
    Dario Campana; Fiscal Year: 2010
    ..The research proposed should not only spur clinical studies of immune cells in patients with refractory ALL but also facilitate the development of effective cell therapies for other neoplasms. ..
  7. B-CELL PROGENITORS AND BONE MARROW MICROENVIRONMENT
    Dario Campana; Fiscal Year: 1993
    ..The techniques established in this project should be applicable to in vitro models for testing of antileukemic agents...
  8. B CELL PROGENITORS AND BONE MARROW MICROENVIRONMENT
    Dario Campana; Fiscal Year: 2000
    ..Establishing a drug sensitivity assay with prognostic relevance could lead to improved rationales for drug selection in individual patients with ALL. ..
  9. DETECTION AND THERAPY OF RESIDUAL LEUKEMIA IN CHILDREN
    Dario Campana; Fiscal Year: 2001
    ..The studies proposed in this application should meet that need and demonstrate the feasibility of clinical management decisions based on MRD detection in children with ALL. ..
  10. Clinical Significance of Residual Myeloid Leukemia
    Dario Campana; Fiscal Year: 2010
    ..Studies in this aim will determine whether higher levels of blood MRD and of circulating leukemic stem cells correlate with a higher risk of relapse. ..